Companies Build on Existing Scientific Collaboration; Early Data Support Advance of "eVLP" Program in CMV CAMBRIDGE, Mass., Sep 15, 2011 (BUSINESS WIRE) -- VBI Vaccines (VBI), a biotechnology company ...
- New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern ...
- VBI-2901 and VBI-2902 selected as trivalent and monovalent coronavirus vaccine candidates, respectively, for an adaptive Phase 1/2 clinical study expected to begin around year-end 2020, subject to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- VBI Vaccines (VBI), a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines, announced today that ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results